Amgen (AMGN) Acquires Global AMG 420 Rights from Boehringer Ingelheim
- AT&T (T) to Acquire Time Warner (TWX) for $107.50/Share
- Rockwell Collins (COL) in Advanced Talks to Acquire B/E Aerospace (BEAV) - WSJ
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Amgen (NASDAQ: AMGN) and Boehringer Ingelheim announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma. BI 836908 (AMG 420) is currently in Phase 1 studies. BI 836908 (AMG 420) was originally licensed to Boehringer Ingelheim by Micromet before the company was acquired by Amgen in 2012.
Under the provisions of the agreement, Amgen will work with Boehringer Ingelheim to assume responsibility for the clinical development of BI 836908 (AMG 420), transfer manufacturing, and lead global regulatory activity moving forward. Amgen will also receive worldwide commercialization rights for BI 836908 (AMG 420). Prior to this agreement, Boehringer Ingelheim held global development and commercialization rights. Financial terms of the agreement are not being disclosed.
"Obtaining global rights to BI 836908 (AMG 420) advances Amgen's immuno-oncology strategy, allowing us to leverage our expertise with the BiTE® platform to target BCMA in the multiple myeloma setting," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Multiple myeloma is a rare and aggressive blood cancer and despite new advances there is currently no cure.1-3 BI 836908 (AMG 420) allows us to explore a potential new treatment approach that harnesses the immune system to fight multiple myeloma."
"Boehringer Ingelheim is delighted that Amgen will continue our successful development of this important compound for multiple myeloma," said Dr. Jörg Barth, corporate senior vice president, Therapy Area Head Oncology at Boehringer Ingelheim. "Given Amgen's focus in this disease area, we are convinced this best supports the future development for BI 836908 (AMG 420) and the goal to ultimately offer new treatment options for patients. Immuno-oncology and T cell engagers remain a key area of focus for Boehringer Ingelheim as well as providing innovative treatments for lung and blood cancers."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) Announces XGEVA vs. Zoledronic Acid Study Met Primary Endpoint; Secondary Endpoints Missed
- Estée Lauder (EL) Enters Agreement to Acquire BECCA Cosmetics
- AT&T (T) Agrees to Acquire Time Warner (TWX) for More than $80 Billion - WSJ
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments, Mergers and Acquisitions
Related EntitiesTwitter, Dividend, Amgen/Micromet, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!